Losartan Market, By indication (Hypertension, Left Ventricular Hypertrophy (LVH), Diabetic Nephropathy, and Others (Stroke, etc.)), By Strength (12.5 mg, 25 mg, 50 mg, and 100 mg), By Product Type (Branded and Generic), By Age Group (Pediatric, Adult, and

The Global Losartan Market is estimated to be valued at USD 1.68 Bn in 2025 and is expected to reach USD 2.23 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.1% from 2025 to 2032. The global Losartan market has witnessed significant growth in recent years, driven by the increasing prevalence of hypertension and cardiovascular diseases worldwide. Losartan, an angiotensin II receptor antagonist, is widely prescribed for the treatment of high blood pressure, heart failure, and diabetic nephropathy. The market's expansion is further fueled by unhealthy lifestyles and rising awareness about the importance of effective blood pressure management. Moreover, the availability of generic Losartan products has increased their accessibility and affordability, contributing to their widespread adoption. As the demand for efficient antihypertensive medications continues to rise, the global Losartan market is poised for substantial growth in the coming years.

Market Dynamics

The global Losartan market is influenced by several key drivers, restraints, and opportunities. The primary driver for market growth is the increasing prevalence of hypertension and related cardiovascular disorders, such as heart failure and stroke. Unhealthy lifestyles characterized by sedentary behavior, obesity, and high-stress levels have led to a significant increase in the incidence of hypertension. Furthermore, the growing awareness about the importance of effective blood pressure management and the availability of affordable generic Losartan products have boosted the market's growth. However, the market also faces certain restraints, such as the presence of alternative antihypertensive medications and potential side effects associated with Losartan use. Additionally, the expiration of patents for branded Losartan products has led to increased competition from generic manufacturers, potentially impacting the market share of key players. Despite these challenges, the market presents promising opportunities for growth, including the development of novel drug delivery systems, the expansion of Losartan's therapeutic applications, and the untapped potential in emerging economies with high hypertension prevalence rates. Moreover, strategic collaborations and mergers among pharmaceutical companies are expected to drive innovation and expand market reach in the coming years.

Key features of the study

• This report provides an in-depth analysis of the global Losartan market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Losartan market based on the following parameters: company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd, Mylan N.V., Organon LLC, Alembic Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd, Teva Pharmaceuticals Usa, Aurobindo Pharma, Lupin Limited, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Torrent Pharmaceuticals Ltd, Cipla Ltd, Glenmark Pharmaceuticals, Alkem Laboratories, Granules India Ltd, and Micro Labs Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global Losartan market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Losartan market.

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
• Hypertension
• Left Ventricular Hypertrophy (LVH)
• Diabetic Nephropathy
• Others (Stroke, etc.)
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
• 5 mg
• 25 mg
• 50 mg
• 100 mg
• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• Branded
• Generic
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
• Male
• Female
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Form Insights (Revenue, USD Bn, 2020 - 2032)
• Tablet
• Powder
• Suspension
• Source Insights (Revenue, USD Bn, 2020 - 2032)
• Contract Manufacturing Organizations
• In-House Manufacturing
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U,S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Organon LLC
• Alembic Pharmaceuticals Ltd
• Macleods Pharmaceuticals Ltd
• Teva Pharmaceuticals USA
• Aurobindo Pharma
• Lupin Limited
• Reddy’s Laboratories
• Sun Pharmaceutical Industries Ltd
• Zydus Cadila
• Torrent Pharmaceuticals Ltd
• Cipla Ltd
• Glenmark Pharmaceuticals
• Alkem Laboratories
• Granules India Ltd
• Micro Labs Ltd

Show more